biotech
- Home
- biotech
Public
Research Note - Rise of the Cashless Economy
- Review
- June 3, 2020
Novatti launches new payments platform for purpose-issued Visa cards
- Review
- September 29, 2020
Latest Articles
Pharmaxis targeting scar-free recovery from burns with world-first trials
One of the world’s most respected surgeons in the field of burns and trauma recovery will lead world-first clinical trials aiming to stop scars forming, particularly after burn injuries, utilising the latest discovery by biopharmaceuticals company Pharmaxis (ASX: PXS). The discovery, known as PXS-6302 has shown promising pre‐clinical results in inhibiting the enzymes that play
Read MorePublic
Pharmaxis sales thriving in US following FDA approval for cystic fibrosis treatment
The world’s most lucrative healthcare market is quickly appreciating Aussie pharmaceuticals company Pharmaxis (ASX: PXS) whose cystic fibrosis (CF) treatment Bronchitol is rapidly emerging as the preferred treatment by CF sufferers in the United States. Researched and manufactured in Australia, Bronchitol gained commercial approval from the US Food and Drug Administration (FDA) in October 2020
Read MorePublic
Paradigm eyes FDA and TGA submission as patient data confirms major joint pain reduction
Clinical data trials being conducted by Paradigm Biopharmaceuticals (ASX: PAR) continue to deliver impressive patient outcomes for sufferers of chronic joint pain and osteoarthritis with 13 new patients having joined the trials and reported significantly better quality of life upon treatment with Zilosul. The most recent round of trials have been conducted in Australia under
Read MorePublic
FDA approves Imugene to commence human trial for lung cancer immunotherapy
Biopharma company Imugene (ASX: IMU) is now on their way towards commercialisation of their lung cancer treatment with approval from the US Food and Drug Administration (FDA) to commence human trials. With the project name PD1-Vaxx in the US, the approval enables Imugene to commence recruiting patients for a clinical trial of the treatment on
Read MorePublic
CLINUVEL to trial new drug addressing irreversible brain damage from by stroke
Leading pharmaceuticals company CLINUVEL (ASX: CUV) is set to commence human trials using the drug afamelanotide to dissolve or remove underlying blood clots in the brain that cause arterial ischaemic stroke (AIS) which accounts for 85% of the 15 million strokes suffered worldwide each year. Current stroke therapies are reliant on early intervention to restore
Read MorePublic
Telix submits FDA application for new prostate cancer imaging product
It may soon be easier for prostate cancer to be diagnosed at an early stage with Telix Pharmaceuticals (ASX: TLX) having submitted their radiopharmaceutical imaging technology to the Food and Drug Administration for approval. The New Drug Application (NDA) comes after completing clinical trials across more than 600 patients which builds on peer-reviewed clinical research
Read MorePublic